Clinical outcomes of antithrombin III-based therapy for patients with portal vein thrombosis: A retrospective, multicenter study.
Korenobu HayamaMasanori AtsukawaAkihito TsubotaChisa KondoMotoh IwasaHiroshi HasegawaKoichi TakaguchiAkemi TsutsuiHaruki UojimaHisashi HidakaHironao OkuboTatsuya SuzukiKentaro MatsuuraToshifumi TadaNaoto KawabeJoji TaniAkihiro MorishitaToru IshikawaYoshitaka AraseYoshihiro FuruichiKeizo KatoKazuhito KawataMakoto ChumaAkito NozakiAtsushi HiraokaTsunamasa WatanabeTatehiro KagawaHidenori ToyodaNobuhiko TaniaiHiroshi YoshidaYasuhito TanakaKatsuhiko Iwakirinull nullPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)
This study suggests that maintenance therapy, favorable response, and absence of PVT progression may suppress or control liver-related events in antithrombin III-based therapy for patients with PVT. Specifically, maintenance therapy could suppress not only liver-related events, but also PVT progression and improve the prognosis.